Papillary Thyroid Microcarcinoma - Do Classical Staging Systems Need to Be Changed?

Zafón, Carles

doi:10.5772/25354

Cited by 1 publication

(1 citation statement)

References 78 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most accepted prognostic factors are age, histological variant, initial extension of the disease, and size of the primary tumour. However, a significant percentage of patients are not correctly classified with these variables, indicating the necessity of better early markers of cancer risk assessment to obtain a fine-tuned prognostic characterization [32] . Furthermore, the currently used clinical scoring systems focus on disease-specific mortality, when, in fact, a system to predict recurrence is most relevant to the vast majority of thyroid cancer patients, since they will have low-risk disease.…”

Section: Differentiated Thyroid Cancermentioning

confidence: 99%

Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine

et al. 2017

Self Cite

View full text Add to dashboard Cite

The management of thyroid nodules, one of the main clinical challenges in endocrine clinical practice, is usually straightforward. Although the most important concern is ruling out malignancy, there are grey areas where uncertainty is frequently present: the nodules labelled as indeterminate by cytology and the extent of therapy when thyroid cancer is diagnosed pathologically. There is evidence that the current available precision medicine tools (from all the “-omics” to molecular analysis, fine-tuning imaging or artificial intelligence) may help to fill present gaps in the future. We present here a commentary on some of the current challenges faced by endocrinologists in the field of thyroid nodules and cancer, and illustrate how precision medicine may improve their diagnostic and therapeutic capabilities in the future.

show abstract

Section: Differentiated Thyroid Cancermentioning

confidence: 99%